Stock BCYP BIG CYPR
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

BIG CYPR

Equities

BCYP

US0891151096

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about BIG CYPR

Big Cypress Acquisition Corp.(NasdaqCM:BCYP) dropped from NASDAQ Composite Index CI
SAB Biotherapeutics, Inc. completed the acquisition of Big Cypress Acquisition Corp. in a reverse merger transaction. CI
Big Cypress Acquisition Corp. Announces Board Changes CI
Certain Common Stock of Big Cypress Acquisition Corp. are subject to a Lock-Up Agreement Ending on 10-JUL-2021. CI
Big Cypress Acquisition : Says First Patient Dosed in SAB Biotherapeutics' Phase 2a Influenza Drug Trial MT
Big Cypress Acquisition : to Merge With SAB Biotherapeutics; Combined Firm to Go Public MT
SAB Biotherapeutics, Inc. entered into nonbinding letter of intent to acquire Big Cypress Acquisition Corp. in a reverse merger transaction for approximately $410 million. CI
Big Cypress Acquisition Corp.(NasdaqCM:BCYP) added to NASDAQ Composite Index CI
Big Cypress Acquisition Corp. announced that it has received $4.172 million in funding from Big Cypress Holdings LLC CI
Big Cypress Acquisition Corp. has completed an IPO in the amount of $100 million. CI
Big Cypress Acquisition Corp. announced that it expects to receive $3.8225 million in funding from Big Cypress Holdings LLC CI
Big Cypress Acquisition Corp. has filed an IPO in the amount of $75 million. CI

Chart BIG CYPR

Chart BIG CYPR
More charts

Company Profile

Big Cypress Acquisition Corp is a blank check company. The Company is formed for the purpose of effecting an initial business combination with one or more target businesses. The Company have not selected any specific target business. The Company may pursue an acquisition opportunity in any industry or sector, and intends to acquire and manage a business in the life sciences industry.
Sector
-
More about the company
  1. Stock Market
  2. Equities
  3. BCYP Stock
  4. News BIG CYPR
  5. Big Cypress Acquisition : Says First Patient Dosed in SAB Biotherapeutics' Phase 2a Influenza Drug Trial